What Is IGF-1 LR3? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. IGF-1 LR3 is not FDA-approved for human therapeutic use. Products sold online as IGF-1 LR3, Long R3 IGF-1, LR3 IGF-1, or “research use only” IGF-1 LR3 may carry serious safety, quality, legal, and anti-doping risks.
Quick answer
IGF-1 LR3, also called Long R3 IGF-1, is a modified analog of insulin-like growth factor-1. It is designed to have altered binding to IGF-binding proteins and longer biological activity than native IGF-1 in certain experimental systems. IGF-1 LR3 is marketed online for muscle growth, localized hypertrophy, recovery, body recomposition, and bodybuilding, but strong human clinical evidence for these uses is lacking. It is not FDA-approved, may carry serious growth-factor risks such as hypoglycemia and abnormal tissue-growth concerns, and IGF-1 analogues are prohibited in sport.
Key facts about IGF-1 LR3
| Question | Answer |
|---|---|
| What is IGF-1 LR3? | A modified long-acting analog of insulin-like growth factor-1. |
| Other names | Long R3 IGF-1, LR3 IGF-1, Long Arg3 IGF-1. |
| Peptide class | Growth factor analog / IGF-1 analog / anabolic growth-factor peptide. |
| Main mechanism | Activates IGF-1 receptor signaling and is designed to have reduced binding to IGF-binding proteins, increasing bioavailability in experimental systems. |
| FDA-approved? | No. IGF-1 LR3 is not an FDA-approved drug. |
| Related FDA-approved drug | Mecasermin is recombinant human IGF-1 approved for specific severe pediatric growth disorders, but it is not IGF-1 LR3. |
| Main studied uses | Cell proliferation, tissue growth, muscle biology, growth-factor signaling, anti-doping detection research, and preclinical models. |
| Human evidence level | Very limited to absent for therapeutic, bodybuilding, recovery, anti-aging, or body-composition use. |
| Animal/lab evidence level | Moderate mechanistic, cell-culture, and animal evidence for potent IGF-1-like biological activity. |
| Common online claims | “Muscle growth,” “localized hypertrophy,” “muscle hyperplasia,” “injury recovery,” “site enhancement,” “anabolic peptide.” |
| Sports status | Prohibited by WADA because IGF-1 and its analogues are prohibited. |
| Main safety concern | Potent growth-factor biology, possible hypoglycemia, edema, abnormal tissue growth, organ-growth effects, cancer-proliferation concerns, and risks from unapproved online products. |
What is IGF-1 LR3?
IGF-1 LR3 is a modified analog of insulin-like growth factor-1. IGF-1 is a naturally occurring growth factor involved in growth, tissue development, metabolism, and anabolic signaling.
IGF-1 LR3 is usually described as Long R3 IGF-1 or Long Arg3 IGF-1. The “R3” refers to an arginine substitution at position 3, and “Long” refers to an additional N-terminal extension. These modifications are designed to reduce binding to IGF-binding proteins and increase biological availability in experimental systems.
A PubMed anti-doping detection paper describes LongR3-IGF-I as one of the IGF-1 analogs, alongside des(1-3)-IGF-I and R3-IGF-I, that are prohibited substances in sport.
A PMC review on IGF-1 monitoring in medicine and sport discusses IGF-1 and IGF-1 analogues in anti-doping and medical-diagnostic contexts.
The key distinction:
IGF-1 LR3 is not the same as normal endogenous IGF-1, not the same as FDA-approved mecasermin, and not a proven human muscle-growth or recovery drug.
How does IGF-1 LR3 work?
IGF-1 LR3 works through IGF-1-related signaling pathways. IGF-1 binds primarily to the IGF-1 receptor, which can influence cell growth, protein synthesis, survival signaling, tissue development, and metabolism.
The reason IGF-1 LR3 is discussed as “long-acting” is that it is designed to bind less strongly to IGF-binding proteins than native IGF-1. IGF-binding proteins normally regulate IGF-1 availability and activity.
In plain English:
IGF-1 LR3 is designed to make IGF-1-like signaling more available and longer-lasting in certain experimental systems.
That is exactly why it is risky.
A growth factor with stronger or longer signaling is not automatically better. It may also increase risks related to low blood sugar, abnormal tissue growth, edema, organ effects, and cell proliferation.
What is IGF-1 LR3 used for?
IGF-1 LR3 is commonly discussed for bodybuilding, muscle growth, localized hypertrophy, tissue repair, injury recovery, and anti-aging. These uses differ sharply in evidence quality.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| Cell growth and proliferation models | Cell-culture evidence | IGF-1 LR3 has biological activity in cell-proliferation systems. | Clinical relevance in humans is not established. |
| Muscle growth | Mostly preclinical / extrapolated | IGF-1 signaling is anabolic and involved in muscle biology. | Human evidence for safe and effective IGF-1 LR3 muscle growth is lacking. |
| Localized muscle growth | Weak / marketing-driven | Online bodybuilding claims are common. | Site-specific hypertrophy in humans is not proven by strong clinical evidence. |
| Injury recovery | Weak / extrapolated | Growth-factor biology may influence repair pathways. | Human tendon, ligament, and muscle-recovery claims are not established. |
| Anti-aging | Unsupported | IGF-1 is involved in growth and repair biology. | No strong evidence supports IGF-1 LR3 as a safe anti-aging therapy. |
| Athletic performance | Unsupported and prohibited | Some athletes seek anabolic effects. | IGF-1 and analogues are prohibited by WADA. |
| Online research-use IGF-1 LR3 | High uncertainty | Sellers market it as a peptide product. | Quality, sterility, identity, concentration, and safety may be unknown. |
What does the research show?
Human evidence
The human evidence for IGF-1 LR3 as a therapeutic, bodybuilding, recovery, or anti-aging compound is very limited to absent.
Most claims about IGF-1 LR3 come from:
- Cell-culture studies
- Animal studies
- IGF-1 biology
- Bodybuilding anecdotes
- Vendor claims
- Anti-doping literature
- Comparisons to full IGF-1 or mecasermin
The practical interpretation:
IGF-1 LR3 should not be treated as clinically proven for human muscle growth, localized hypertrophy, injury recovery, or anti-aging.
Cell-culture and mechanistic evidence
IGF-1 LR3 has research value because it can produce IGF-1-like biological activity in experimental models.
A PubMed study on recombinant IGF-1 and LR3 IGF-1 expression reported production of human IGF-1 and Long R3 IGF-1 and noted bioactivity in cell-proliferation assays compared with standard IGF-1.
This supports the basic biological claim:
IGF-1 LR3 has IGF-1-like growth-factor activity in experimental systems.
It does not prove that online IGF-1 LR3 safely builds muscle in humans.
Animal evidence
Animal studies show IGF-1 LR3 can have systemic growth effects.
A PubMed guinea pig study reported that Long R3 IGF-I infusion stimulated organ growth while reducing plasma IGF-I, IGF-II, and IGF-binding protein concentrations.
A PubMed rat study investigated LR3 IGF-I infusion and anabolic effects in rats.
The practical interpretation:
Animal data show IGF-1 LR3 can affect tissues, but that is not automatically good. Organ-growth effects and systemic growth-factor activity are exactly why unsupervised use is risky.
Anti-doping detection evidence
IGF-1 LR3 is also studied because it is abused in sport.
A PubMed detection paper states that IGF-I and its analogs LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I are prohibited substances in sport.
WADA also has research focused on detecting human IGF-1 and analogues including Long R3 IGF-1. The WADA research page describes methods for identifying IGF-1 analogues including LONG R3 IGF-1 and des(1-3) IGF-1.
The practical interpretation:
IGF-1 LR3 is not just a research compound. It is specifically relevant to anti-doping because of performance-enhancement abuse risk.
Cancer and proliferation concerns
This is one of the biggest safety issues with IGF-related compounds.
The National Cancer Institute definition of insulin-like growth factor states that IGF stimulates the growth of many cell types and that higher-than-normal IGF-1 levels may increase the risk of several types of cancer.
A PMC review on mechanisms by which IGF-I may promote cancer discusses how IGF-I signaling may contribute to cancer biology, including cell growth and survival pathways.
This does not prove that IGF-1 LR3 causes cancer in humans.
But it does mean simplistic “growth equals recovery” marketing is irresponsible.
The practical interpretation:
Any compound designed to increase growth-factor signaling should be evaluated with cancer, abnormal tissue growth, and cell-proliferation risk in mind.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “IGF-1 LR3 is a modified IGF-1 analog.” | Supported | It is commonly described as Long R3 IGF-1, a modified IGF-1 analog. |
| “IGF-1 LR3 has IGF-1-like activity.” | Supported preclinically | Cell and animal studies support biological activity. |
| “IGF-1 LR3 builds muscle in humans.” | Not established | Strong controlled human clinical evidence is lacking. |
| “IGF-1 LR3 causes localized muscle growth.” | Not established | This is mostly bodybuilding marketing, not clinical proof. |
| “IGF-1 LR3 repairs tendons or injuries.” | Not established | Repair claims are extrapolated from growth-factor biology. |
| “IGF-1 LR3 is FDA-approved.” | False | IGF-1 LR3 is not FDA-approved. |
| “IGF-1 LR3 is the same as mecasermin.” | False | Mecasermin is recombinant human IGF-1; IGF-1 LR3 is a modified analog. |
| “IGF-1 LR3 is safe because IGF-1 exists naturally.” | False | Natural pathway involvement does not prove safety, especially for potent analogs. |
| “IGF-1 LR3 is allowed for athletes.” | False | IGF-1 and its analogues are prohibited by WADA. |
| “Research-use IGF-1 LR3 is clinically proven.” | False | Research-use products are not FDA-approved consumer therapeutic products. |
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not FDA-approved.
There is an FDA-approved IGF-1-related drug, but it is not IGF-1 LR3.
Mecasermin is recombinant human IGF-1 used for specific severe pediatric growth disorders. That does not make IGF-1 LR3 approved, interchangeable, or appropriate for bodybuilding, anti-aging, or recovery.
The key distinction:
IGF-1 LR3 is an unapproved IGF-1 analog. It should not be confused with FDA-approved mecasermin or normal endogenous IGF-1.
Is IGF-1 LR3 legal?
IGF-1 LR3’s legal status depends on product type, intended use, jurisdiction, and how it is sold.
The practical answer is simple:
IGF-1 LR3 is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.
Some sellers market IGF-1 LR3 as a research peptide. That does not make it safe, approved, legal, or appropriate for consumer use.
The blunt version:
Buying “research use only” IGF-1 LR3 online is not the same as receiving an FDA-approved prescription medication from a legitimate pharmacy.
Is IGF-1 LR3 banned in sports?
Yes. IGF-1 LR3 is prohibited in sport.
The WADA Prohibited List lists insulin-like growth factor-1, also called IGF-1, and its analogues as prohibited under peptide hormones, growth factors, related substances, and mimetics.
The USADA IGF-1 guidance states that IGF-1 is prohibited on the WADA Prohibited List and is included in the class of peptide hormones, growth factors, and related substances.
A PubMed anti-doping detection paper specifically names LongR3-IGF-I as an IGF-1 analog prohibited in sport.
For athletes, the answer is simple:
Do not use IGF-1 LR3 if you are subject to anti-doping rules.
Safety and side effects
IGF-1 LR3 has real biological activity. It should not be treated like a harmless supplement.
Possible or theoretical concerns include:
- Hypoglycemia or low blood sugar
- Headache
- Edema or fluid retention
- Injection-site reactions
- Joint or muscle pain
- Abnormal tissue growth
- Organ-growth concerns
- Changes in glucose metabolism
- Increased cell proliferation
- Possible acceleration of existing or dormant malignancies
- Product-quality and sterility risks from online sources
- Mislabeling or incorrect concentration
- Anti-doping consequences for athletes
IGF-1 biology is not trivial. IGF-1 is involved in growth, anabolic signaling, cell survival, and metabolism. That is why it is medically and biologically important, but also why unsupervised use is risky.
A serious evaluation of IGF-1 LR3 should separate controlled laboratory research from online bodybuilding peptide use.
IGF-1 LR3 vs similar peptides and drugs
| Compound | Category | Main difference |
|---|---|---|
| IGF-1 LR3 | Modified long-acting IGF-1 analog | Designed for reduced IGF-binding protein interaction and longer activity; not FDA-approved. |
| IGF-1 DES | Truncated IGF-1 analog | Lacks first three amino acids; often discussed for local potency; not FDA-approved. |
| Mecasermin | Recombinant human IGF-1 | FDA-approved for specific severe pediatric growth disorders; not the same as IGF-1 LR3. |
| Human growth hormone | Recombinant hormone | Stimulates IGF-1 production indirectly; different from injecting IGF-1 analogs. |
| MGF | Mechano growth factor / IGF-1 splice variant-related | Different IGF-related peptide category; also prohibited in sport. |
| CJC-1295 | GHRH analog | Stimulates endogenous GH release upstream; not an IGF-1 analog. |
| Ipamorelin | GH secretagogue | Stimulates GH through ghrelin receptor signaling; not an IGF-1 analog. |
| BPC-157 | Experimental repair peptide | Not an IGF-1 growth factor analog. |
The key distinction:
IGF-1 LR3 is directly in the growth-factor category. It is not a GH secretagogue, not a GLP-1 drug, not a repair peptide, and not a normal supplement.
Why is IGF-1 LR3 sold as “research use only”?
Some online sellers use “research use only” language to sell IGF-1 LR3 outside normal prescription-drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Laboratory IGF-1 LR3 | Research compound used in controlled experimental settings. |
| FDA-approved IGF-1 LR3 | Does not currently exist. |
| Mecasermin | FDA-approved recombinant human IGF-1 for specific pediatric growth disorders. |
| Research-use IGF-1 LR3 | Not an FDA-approved consumer therapeutic product. |
| Online peptide IGF-1 LR3 | Higher risk for identity, purity, sterility, dosing, and safety problems. |
How to evaluate IGF-1 LR3 claims online
| Claim | What to verify |
|---|---|
| “FDA-approved IGF-1 LR3” | False. IGF-1 LR3 is not FDA-approved. |
| “Same as mecasermin” | False. Mecasermin is recombinant full-length human IGF-1, not IGF-1 LR3. |
| “Clinically proven muscle growth” | Look for controlled human trials, not cell studies or bodybuilding anecdotes. |
| “Localized muscle growth” | Marketing claim unless supported by human clinical evidence. |
| “Heals tendons and ligaments” | Check whether evidence is human outcome data or extrapolated growth-factor theory. |
| “No side effects” | False. IGF-related growth-factor signaling can affect glucose, tissue growth, and cell proliferation. |
| “Safe because IGF-1 is natural” | False. Natural biological pathways can still be dangerous when manipulated. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | False. IGF-1 and its analogues are prohibited by WADA. |
| “Third-party tested” | Ask for batch-specific HPLC, LC-MS, identity, purity, sterility, endotoxin, and stability data. |
Bottom line
IGF-1 LR3 is a modified long-acting analog of IGF-1 designed to increase IGF-1-like signaling availability in experimental systems. It is biologically potent, but that is not the same as being clinically proven or safe for human use.
The most defensible conclusion is:
IGF-1 LR3 is a high-risk research growth factor, not a proven consumer peptide. It is not FDA-approved, lacks strong human clinical evidence for bodybuilding or recovery claims, may carry serious growth-factor safety concerns, and is prohibited in sport as an IGF-1 analogue.
FAQ
What is IGF-1 LR3?
IGF-1 LR3 is a modified long-acting analog of insulin-like growth factor-1. It is also called Long R3 IGF-1 or Long Arg3 IGF-1.
What does IGF-1 LR3 do?
IGF-1 LR3 activates IGF-1-related growth-factor signaling. In experimental systems, it can influence cell growth, proliferation, hypertrophy, and tissue-related pathways.
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not FDA-approved. It should not be confused with mecasermin, which is FDA-approved recombinant human IGF-1 for specific severe pediatric growth disorders.
Is IGF-1 LR3 the same as IGF-1?
No. IGF-1 LR3 is a modified analog of IGF-1 designed to have altered binding to IGF-binding proteins and longer activity in experimental systems.
Is IGF-1 LR3 the same as IGF-1 DES?
No. IGF-1 LR3 and IGF-1 DES are different IGF-1 analogs. IGF-1 LR3 is a long-acting modified analog, while IGF-1 DES is a truncated analog lacking the first three amino acids.
Does IGF-1 LR3 build muscle?
Human evidence is not strong enough to say IGF-1 LR3 safely or reliably builds muscle. Most muscle-growth claims are extrapolated from IGF-1 biology, cell studies, animal studies, and bodybuilding anecdotes.
Does IGF-1 LR3 cause localized muscle growth?
Localized muscle-growth claims are common online, but strong controlled human evidence is lacking. This claim should be treated as unproven.
Is IGF-1 LR3 safe?
IGF-1 LR3 does not have enough human safety data to call it safe. Possible concerns include hypoglycemia, fluid retention, abnormal tissue growth, cell-proliferation effects, cancer-related concerns, and online product-quality risks.
Is IGF-1 LR3 legal?
IGF-1 LR3 is not an FDA-approved drug. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.
Is IGF-1 LR3 banned in sports?
Yes. IGF-1 and its analogues are prohibited by WADA. LongR3-IGF-I is specifically discussed in anti-doping literature as a prohibited IGF-1 analog.
Why do sellers call IGF-1 LR3 “research use only”?
Sellers often use “research use only” language because IGF-1 LR3 is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with IGF-1 LR3?
The biggest risks are using an unapproved growth-factor analog without medical supervision, relying on bodybuilding claims instead of human evidence, possible hypoglycemia or abnormal growth effects, and buying online products with uncertain identity, purity, sterility, concentration, and safety.
Sources
- PubMed: Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I
- PMC: Insulin-Like Growth Factor-1 and Its Monitoring in Medical Diagnostic and in Sports
- PubMed: Long R3 IGF-I infusion stimulates organ growth in guinea pigs
- PubMed: LR3 IGF-I infusion and anabolic effects in rats
- PubMed: Recombinant expression of IGF-1 and LR3 IGF-1
- NCI Dictionary: Insulin-like Growth Factor
- PMC: Mechanisms by which IGF-I May Promote Cancer
- MedlinePlus: IGF-1 Insulin-like Growth Factor 1 Test
- USADA: IGF-1 and the World Anti-Doping Agency Prohibited List
- WADA: Statement on the Prohibited Substance IGF-1
- WADA: Prohibited List
- WADA: Qualitative and Quantitative Determination of Insulin-like Growth Factor-I Analogues
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is a modified long-acting analog of insulin-like growth factor-1. It is also called Long R3 IGF-1 or Long Arg3 IGF-1.
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not FDA-approved. It should not be confused with mecasermin, which is FDA-approved recombinant human IGF-1 for specific severe pediatric growth disorders.
Is IGF-1 LR3 the same as IGF-1?
No. IGF-1 LR3 is a modified analog of IGF-1 designed to have altered binding to IGF-binding proteins and longer activity in experimental systems.
Is IGF-1 LR3 the same as IGF-1 DES?
No. IGF-1 LR3 and IGF-1 DES are different IGF-1 analogs. IGF-1 LR3 is a long-acting modified analog, while IGF-1 DES is a truncated analog lacking the first three amino acids.
Does IGF-1 LR3 build muscle?
Human evidence is not strong enough to say IGF-1 LR3 safely or reliably builds muscle. Most muscle-growth claims are extrapolated from IGF-1 biology, cell studies, animal studies, and bodybuilding anecdotes.
Is IGF-1 LR3 safe?
IGF-1 LR3 does not have enough human safety data to call it safe. Possible concerns include hypoglycemia, fluid retention, abnormal tissue growth, cell-proliferation effects, cancer-related concerns, and online product-quality risks.
Is IGF-1 LR3 banned in sports?
Yes. IGF-1 and its analogues are prohibited by WADA. LongR3-IGF-I is specifically discussed in anti-doping literature as a prohibited IGF-1 analog.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]NCI Dictionary: Insulin-like Growth Factor
Medical Reference
- [7]
- [8]MedlinePlus: IGF-1 Insulin-like Growth Factor 1 Test
Medical Reference
- [9]
- [10]
- [11]WADA: Prohibited List
Anti Doping
- [12]
Last updated May 9, 2026